Citations

Clear

4207 citation(s) found for "Chen, Yu".

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Kurtova, Antonina V., Balakrishnan, Kumudha, Chen, Rong , Schnabl, Susanne, Quiroga, Maite P., Sivina, Mariela , Keating, Michael J. , Shehata, Medhat , Jäger, Ulrich, Ding, Wei , Wierda, William G. , Estrov, Zeev E. , Gandhi, Varsha V. , Kay, Neil E. , Plunkett, William K. , Burger, Jan A.

Mayo Clinic

Blood | September 18, 2009 | Volume: 114 | Issue: 20 | Pages: 4441-4450

10.1182/blood-2009-07-233718 | PMID 19762485 Get It

Abstract Marrow stromal cells (MSCs) provide important survival and drug resistance signals to chronic lymphocytic leukemia (CLL) cells, but current models to analyze CLL–MSC interactions are heterogeneous. Therefore, we tested different human and murine MSC lines and primary human MSCs for their ability to protect CLL cells from spontaneous and drug-induced apoptosis. Our results show that both human and murine MSCs are equally effective in protecting CLL cells from fludarabine-induced apoptosis. This protective effect was sustained over a wide range of CLL–MSC ratios (5:1 to 100:1), and the levels of protection were reproducible in 4 different laboratories. Human and murine MSCs also protected CLL cells from dexamethasone- and cyclophosphamide-induced apoptosis. This protection required cell–cell contact and was virtually absent when CLL cells were separated from the MSCs by micropore filters. Furthermore, MSCs maintained Mcl-1 and protected CLL cells from spontaneous and fludarabine-induced Mcl-1 and PARP cleavage. Collectively, these studies define common denominators for CLL cocultures with MSCs. They also provide a reliable, validated tool for future investigations into the mechanism of MSC–CLL cross talk and for drug testing in a more relevant fashion than the commonly used suspension cultures.
MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma
Yang, Hushan , Gu, Jian , Wang, Kenneth K. , Zhang, Wei , Xing, Jinliang , Wu, Xifeng , Chen, Zhi‐Nan , Ajani, Jaffer A. , Gu, Jian

Mayo Clinic

Clinical Cancer Research | September 8, 2009 | Volume: 15 | Issue: 18 | Pages: 5744-5752

10.1158/1078-0432.ccr-09-0385 | PMID 19737949 Get It

Abstract Purpose: Esophageal adenocarcinoma is a highly aggressive malignancy that frequently develops from Barrett's esophagus, a premalignant pathologic change occurring in the lower end of the esophagus. Identifying Barrett's esophagus patients at high risk of malignant transformation is essential to the prevention of esophageal adenocarcinoma. Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated. Experimental Design: In this study, we analyzed the expression patterns of 470 human miRNAs using Agilent miRNA microarray in 32 disease/normal-paired tissues from 16 patients diagnosed with Barrett's esophagus of either low- or high-grade dysplasia, or esophageal adenocarcinoma. Results: Using unsupervised hierarchical clustering and class comparison analyses, we found that miRNA expression profiles in tissues of Barrett's esophagus with high-grade dysplasia were significantly different from their corresponding normal tissues. Similar findings were observed for esophageal adenocarcinoma, but not for Barrett's esophagus with low-grade dysplasia. The expression patterns of selected miRNAs were further validated using quantitative reverse transcription real-time PCR in an independent set of 75 pairs of disease/normal tissues. Finally, we identified several miRNAs that were involved in the progressions from low grade-dysplasia Barrett's esophagus to esophageal adenocarcinoma. Conclusions: We showed that miRNAs were involved in the development and progression of esophageal adenocarcinoma. The identified significant miRNAs that may become potential targets for early detection, chemoprevention, and treatment of esophageal cancer. (Clin Cancer Res 2009;15(18):5744–52)
Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Lu, Kan , Zhu, Shaojun , Cvrljevic, Anna N. , Huang, Tiffany , Sarkaria, Shawn , Ahkavan, David, Dinca, Eduard B., Plaisier, Seema B. , Oderberg, Isaac M. , Chen, Zugen, Caldwell, Jeremy S. , Xie, Yongmin, Loo, Joseph A. , Seligson, David B., Chakravari, Arnab, Lee, Francis Y. , Weinmann, Roberto, Nelson, Stanley F., Bergers, Gabriele , Graeber, Thomas G. , Furnari, Frank B. , James, C. David , Cavenee, Webster K. , Johns, Terrance G. , Nelson, Stanley F. , Dang, Julie H. T. , Lee, Yohan , Cloughesy, Timothy F. , Mischel, Paul S.

Mayo Clinic

Cancer Research | August 19, 2009 | Volume: 69 | Issue: 17 | Pages: 6889-6898

10.1158/0008-5472.can-09-0347 | PMID 19690143 Get It

Abstract Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived. We show that the Src family kinases (SFK) Fyn and Src are effectors of oncogenic EGFR signaling, enhancing invasion and tumor cell survival in vivo. Expression of a constitutively active EGFR mutant, EGFRvIII, resulted in activating phosphorylation and physical association with Src and Fyn, promoting tumor growth and motility. Gene silencing of Fyn and Src limited EGFR- and EGFRvIII-dependent tumor cell motility. The SFK inhibitor dasatinib inhibited invasion, promoted tumor regression, and induced apoptosis in vivo, significantly prolonging survival of an orthotopic glioblastoma model expressing endogenous EGFRvIII. Dasatinib enhanced the efficacy of an anti-EGFR monoclonal antibody (mAb 806) in vivo, further limiting tumor growth and extending survival. Examination of a large cohort of clinical samples showed frequent coactivation of EGFR and SFKs in glioblastoma patients. These results establish a mechanism linking EGFR signaling with Fyn and Src activation to promote tumor progression and invasion in vivo and provide rationale for combined anti-EGFR and anti-SFK targeted therapies. [Cancer Res 2009;69(17):6889–98]
Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2
Evans, D. Gareth , Kalamarides, Michel , Hunter‐Schaedle, Kim, Allen, Jeffrey C. , Babovic-Vuskanovic, Dusica, Belzberg, Allan J. , Bollag, Gideon , Chen, Ruihong , DiTomaso, Emmanuelle, Golfinos, John G. , Harris, Gordon J. , Jacob, Abraham, Kalpana, Ganjam V. , Karajannis, Matthias A. , Korf, Bruce R. , Law, Meng , McClatchey, Andrea I. , Packer, Roger J. , Roehm, Pamela C. , Rubenstein, Allan E., Slattery, William H. , Tonsgard, James H. , Widemann, Brigitte C. , Yohay, Kaleb , Giovannini, Marco , Blakeley, Jaishri O. , Kurzrock, Razelle , Welling, D. Bradley , Evans, D Gareth , Karajannis, Matthias A

Mayo Clinic

Clinical Cancer Research | August 12, 2009 | Volume: 15 | Issue: 16 | Pages: 5032-5039

10.1158/1078-0432.ccr-08-3011 | PMID 19671848 Get It

Abstract Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics. (Clin Cancer Res 2009;15(16):5032–9)
Axon Regeneration through Scaffold into Distal Spinal Cord after Transection
Chen, Bing Kun, Ruiter, Godard C. W. de , Spinner, Robert J. , Yaszemski, Michael J. , Currier, Bradford L. , Windebank, Anthony J. , Knight, Andrew Michael

Mayo Clinic

Journal of Neurotrauma | June 23, 2009 | Volume: 26 | Issue: 10 | Pages: 1759-1771

10.1089/neu.2008.0610 Get It

Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
Pan, Shuchong, Chen, Horng H. , Dickey, Deborah M., Boerrigter, Guido, Lee, Candace, Kleppe, Laurel S., Redfield, Margaret M. , Potter, Lincoln R. , Burnett, John C. , Simari, Robert D., Lee, Candace Y.W., Hall, Jennifer L. , Lerman, Amir

Mayo Clinic

Proceedings of the National Academy of Sciences | June 18, 2009 | Volume: 106 | Issue: 27 | Pages: 11282-11287

10.1073/pnas.0811851106 | PMID 19541613 Get It

Alternative RNA splicing may provide unique opportunities to identify drug targets and therapeutics. We identified an alternative spliced transcript for B-type natriuretic peptide (BNP) resulting from intronic retention. This transcript is present in failing human hearts and is reduced following mechanical unloading. The intron-retained transcript would generate a unique 34 amino acid (aa) carboxyl terminus while maintaining the remaining structure of native BNP. We generated antisera to this carboxyl terminus and identified immunoreactivity in failing human heart tissue. The alternatively spliced peptide (ASBNP) was synthesized and unlike BNP, failed to stimulate cGMP in vascular cells or vasorelax preconstricted arterial rings. This suggests that ASBNP may lack the dose-limiting effects of recombinant BNP. Given structural considerations, a carboxyl-terminal truncated form of ASBNP was generated (ASBNP.1) and was determined to retain the ability of BNP to stimulate cGMP in canine glomerular isolates and cultured human mesangial cells but lacked similar effects in vascular cells. In a canine-pacing model of heart failure, systemic infusion of ASBNP.1 did not alter mean arterial pressure but increased the glomerular filtration rate (GFR), suppressed plasma renin and angiotensin, while inducing natriuresis and diuresis. Consistent with its distinct in vivo effects, the activity of ASBNP.1 may not be explained through binding and activation of NPR-A or NPR-B. Thus, the biodesigner peptide ASBNP.1 enhances GFR associated with heart failure while lacking the vasoactive properties of BNP. These findings demonstrate that peptides with unique properties may be designed based on products of alternatively splicing.
Structural Basis of Ist1 Function and Ist1–Did2 Interaction in the Multivesicular Body Pathway and Cytokinesis
Xiao, Junyu , Chen, Xiaowei , Davies, Brian A., Saltiel, Alan R. , Katzmann, David J. , Xu, Zhaohui

Mayo Clinic

Molecular Biology of the Cell | May 29, 2009 | Volume: 20 | Issue: 15 | Pages: 3514-3524

10.1091/mbc.e09-05-0403 | PMID 19477918 Get It

The ESCRT machinery functions in several important eukaryotic cellular processes. The AAA-ATPase Vps4 catalyzes disassembly of the ESCRT-III complex and may regulate membrane deformation and vesicle scission as well. Ist1 was proposed to be a regulator of Vps4, but its mechanism of action was unclear. The crystal structure of the N-terminal domain of Ist1 (Ist1NTD) reveals an ESCRT-III subunit-like fold, implicating Ist1 as a divergent ESCRT-III family member. Ist1NTD specifically binds to the ESCRT-III subunit Did2, and cocrystallization of Ist1NTD with a Did2 fragment shows that Ist1 interacts with the Did2 C-terminal MIM1 (MIT-interacting motif 1) via a novel MIM-binding structural motif. This arrangement indicates a mechanism for intermolecular ESCRT-III subunit association and may also suggest one form of ESCRT-III subunit autoinhibition via intramolecular interaction.
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide
Sheng, Wei , Chen, Xianghong , Rocha, Kathy, Epling‐Burnette, Pearlie K. , Djeu, Julie Y., Byrd, John C. , Sokol, Lubomir , Lawrence, Nick, Pireddu, Roberta , Dewald, Gordon W., Williams, Ann H., Maciejewski, Jaroslaw P. , List, Alan F. , Byrd, John C. , Liu, Qing , Sokol, Lubomir , Byrd, John C

Mayo Clinic

Proceedings of the National Academy of Sciences | May 26, 2009 | Volume: 106 | Issue: 31 | Pages: 12974-12979

10.1073/pnas.0811267106 | PMID 19470455 Get It

Lenalidomide is the first karyotype-selective therapeutic approved for the treatment of myelodysplastic syndromes (MDS) owing to high rates of erythroid and cytogenetic response in patients with chromosome 5q deletion [del(5q)]. Although haploinsufficiency for the RPS14 gene and others encoded within the common deleted region (CDR) have been implicated in the pathogenesis of the del(5q) phenotype, the molecular basis of the karyotype specificity of lenalidomide remains unexplained. We focused our analysis on possible haplodeficient enzymatic targets encoded within the CDR that play key roles in cell-cycle regulation. We show that the dual specificity phosphatases, Cdc25C and PP2Acα, which are coregulators of the G 2 -M checkpoint, are inhibited by lenalidomide. Gene expression was lower in MDS and acute myeloid leukemia (AML) specimens with del(5q) compared with those with alternate karyotypes. Lenalidomide inhibited phosphatase activity either directly (Cdc25C) or indirectly (PP2A) with corresponding retention of inhibitory phospho-tyrosine residues. Treatment of del(5q) AML cells with lenalidomide induced G 2 arrest and apoptosis, whereas there was no effect in nondel(5q) AML cells. Small interfering RNA (shRNA) suppression of Cdc25C and PP2Ac α gene expression recapitulated del(5q) susceptibility to lenalidomide with induction of G 2 arrest and apoptosis in both U937 and primary nondel(5q) MDS cells. These data establish a role for allelic haplodeficiency of the lenalidomide inhibitable Cdc25C and PP2Acα phosphatases in the selective drug sensitivity of del(5q) MDS.
Growth of the Pediatric Skeleton: A Primer for Radiologists.
Chen, Edem F., Chen, Edem

Mayo Clinic

American Journal of Roentgenology | May 19, 2009 | Volume: 192 | Issue: 6 | Pages: W353-W353

10.2214/ajr.08.2198 Get It

Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium
Gaudet, Mia M., Cox, Angela , Camp, Nicola J. , Goode, Ellen L. , Humphreys, Manjeet K., Dunning, Alison M. , Giles, Graham G. , Severi, Gianluca , Baglietto, Laura , English, Dallas R. , Chang‐Claude, Jenny , Flesch‐Janys, Dieter, Abbas, Sascha, Salazar, Ramona, Mannermaa, Arto, Kataja, Vesa , Kosma, Veli-Matti, Lindblom, Annika , Margolin, Sara , Heikkinen, Tuomas , Kämpjärvi, Kati, Aaltonen, Kirsimari, Nevanlinna, Heli , Bogdanova, Natalia , Coinac, Irina, Schürmann, Peter , Dörk, Thilo , Bartram, Claus R., Schmutzler, Rita K., Tchatchou, Sandrine, Burwinkel, Barbara , Brauch, Hiltrud , Torres, Diana , Hamann, Ute, Justenhoven, Christina , Ribas, Gloría , Flyger, Henrik L., Peto, Julian , Fletcher, Olivia , Johnson, Nichola , dos‐Santos‐Silva, Isabel , Fasching, Peter A. , Beckmann, Matthias W. , Strick, Reiner , Ekici, Arif B. , Schmidt, Marjanka K. , Leeuwen, Flora E. van , Veer, Laura J. van’t , Southey, Melissa C. , Hopper, John L. , Apicella, Carmel, Haiman, Christopher A., Henderson, Brian E., Kolonel, Laurence N. , Kristensen, Vessela N. , Alnæs, Grethe Grenaker, Hunter, David J. , Cox, David G. , Hankinson, Susan E. , Seynaeve, Caroline, Tollenaar, Rob A.�E.�M. , Lissowska, Jolanta , Brinton, Louise A. , Pepłońska, Beata , Czene, Kamila , Li, Yuqing , Liu, Jianjun , Balasubramanian, Sabapathy P. , Rafii, Saeed , Reed, Malcolm , Pooley, Karen A. , Conroy, Don, Baynes, Caroline, Kang, Daehee , Yoo, Keun-Young, Noh, Dong‐Young , Ahn, Sei-Hyun, Shen, Chen‐Yang , Wang, Hui‐Chun , Yu, Jyh-Cherng, Wu, Pei-Ei, Ziogoas, Argyrios, Egan, Kathleen M. , Titus‐Ernstoff, Linda, Dietz, Amy Trentham, Sigurdson, Alice J., Bhatti, Parveen , Allen‐Brady, Kristina , Cannon‐Albright, Lisa , Wong, Jathine , Group, Australian Ovarian Cancer Study, Chenevix‐Trench, Georgia , Spurdle, Amanda B. , Beesley, Jonathan, Easton, Doug , García‐Closas, Montserrat , Thorne, Heather , Li, Yuqing , Milne, Roger L. , Morrison, Jonathan J. , Couch, Fergus J. , Olson, Janet E. , Wang, Xianshu , Mannermaa, Arto, Arias, José Ignacio , Benı́tez, Javier , Bojesen, Stig E. , Nordestgaard, Børge G. , Flyger, Henrik, Broeks, Annegien , Marchand, Loı̈c Le , Kraft, Peter , Vreeswijk, Maaike P.G. , Devilee, Peter , Chanock, Stephen Jacob , Hall, Per N , Anton‐Culver, Hoda , Newcomb, Polly A. , Alexander, Bruce H. , Group, Australian Ovarian Cancer Study, Pharoah, Paul D.P. , Nevanlinna, H , Dörk, Thilo , Giles, Graham G , Spurdle, Amanda B , Lissowska, Jolanta , Southey, Melissa C , English, Dallas R , Cannon-Albright, Lisa A , Dunning, Alison M , Cox, Angela , Torres, Diana , García-Closas, Montserrat , Schmidt, Marjanka K , Severi, Gianluca , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Bhatti, Parveen , Czene, Kamila , Rafii, Saeed , Baglietto, Laura , Fletcher, Olivia , Brauch, Hiltrud , Lindblom, Annika , Liu, Jing , Kang, Daehee , Li, Yuqing

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2009 | Volume: 18 | Issue: 5 | Pages: 1610-1616

10.1158/1055-9965.epi-08-0745 | PMID 19423537 Get It

Abstract Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size. These polymorphisms were genotyped in more than 30,000 breast cancer cases and 30,000 controls, primarily of European descent, from 30 studies in the Breast Cancer Association Consortium. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of association. We found that the minor alleles for these polymorphisms were not related to invasive breast cancer risk overall in women of European descent: ECCR4 per-allele OR (95% CI) = 0.99 (0.97-1.02), minor allele frequency = 27.5%; TNF 1.00 (0.95-1.06), 5.0%; CASP10 1.02 (0.98-1.07), 6.5%; PGR 1.02 (0.99-1.06), 15.3%; and BID 0.98 (0.86-1.12), 1.7%. However, we observed significant between-study heterogeneity for associations with risk for single-nucleotide polymorphisms (SNP) in CASP10, PGR, and BID. Estimates were imprecise for women of Asian and African descent due to small numbers and lower minor allele frequencies (with the exception of BID SNP). The ORs for each copy of the minor allele were not significantly different by estrogen or progesterone receptor status, nor were any significant interactions found between the polymorphisms and age or family history of breast cancer. In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent. (Cancer Epidemiol Biomarkers Prev 2009;18(5):1610–6)